Pyripyropene A is a potent and selective inhibitor of sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2)(IC50 of 0.07 μM).

Pyripyropene A inhibits VEGF (20 ng/ml)-induced migration and tubular formation of HUVECs in dose-dependent fashion. Pyripyropene A do not show growth inhibitory effects against KB3-1, K562 and Neuro2A cells.Pyripyropene A exhibits anti-proliferative activity against HUVECs(IC50 value of 1.8 μM)[1].

Pyripyropene A-treated mice display reduction of atherogenic lesion areas in the aortae and heart. Pyripyropene A inhibits the hepatic e acyl–coenzyme A:cholesterol acyltransferase 2 (ACAT2) activity in vivo[3]. Pyripyropene A displays a half-life (t1/2) of 0.693/λ, where λ represented the terminal slope of the log-linear portion of concentration time profile[4].

147444-03-9

C31H37NO10

583.63

Pyripyropene A

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years